EphA2 antibody | knockout validation | Bethyl Laboratories A302-024A

DOI

//dx.doi.org/10.13070/ko.en.7.2113

Date

2017-01-23

This is a knockout-validated antibody summary, based on the publication "EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Rabbit polyclonal

Company: Bethyl Laboratories

Antibody: EphA2

Catalog number: A302-024A

Summary: Rabbit polyclonal antibody raised against a peptide sequence corresponding to residues within the region 150-200 of human EphA2. This epitope is within the N-terminal region of EphA2. Supplier recommended for WB, IF and IHC. Reacts with human EphA2 (predicted to react with sheep, horse, Guinea pig, pig, orangutan, Rhesus monkey, gorilla, chimpanzee, crab-eating macaque, little brown bat and Northern white-cheeked gibbon based on 100% sequence homology).

Validation Method

Western blot

Sample

Lysates of lung tumor tissue from wild-type and EphA2 knockout mice.

Blocking agent

TBS-T containing 55 milk powder.

Primary incubation

Anti-EphA2 antibody diluted 1:1000.

Secondary incubation

HRP-conjugated anti-rabbit IgG (Promega).

Detection

Clarity Western ECL reagent (BioRad).

Figure

Please see Figure S4 in [1].

References

Amato K, Wang S, Tan L, Hastings A, Song W, Lovly C, et al. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Res. 2016;76:305-18 pubmed publisher